Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.
Hyundai Bioscience Co. Ltd (048410) - Total Liabilities
Latest total liabilities as of September 2025: ₩6.34 Billion KRW
Based on the latest financial reports, Hyundai Bioscience Co. Ltd (048410) has total liabilities worth ₩6.34 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hyundai Bioscience Co. Ltd - Total Liabilities Trend (2002–2024)
This chart illustrates how Hyundai Bioscience Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hyundai Bioscience Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Hyundai Bioscience Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ratch Group Public Company Limited
BK:RATCH
|
Thailand | ฿130.36 Billion |
|
Univest Corporation Pennsylvania
NASDAQ:UVSP
|
USA | $7.49 Billion |
|
Craftsman Automation Limited
NSE:CRAFTSMAN
|
India | ₹52.36 Billion |
|
Guangdong Sky Dragon Printing Ink Group Co Ltd
SHE:300063
|
China | CN¥1.65 Billion |
|
Aptus Value Housing Finance India Limited
NSE:APTUS
|
India | ₹76.00 Billion |
|
Medicover AB Series B
LSE:0RPS
|
UK | Skr1.83 Billion |
|
Northern Data AG
PINK:NDTAF
|
USA | $819.46 Million |
|
Alliance Material Co., Ltd.
TWO:3595
|
Taiwan | NT$110.32 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Hyundai Bioscience Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hyundai Bioscience Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hyundai Bioscience Co. Ltd (2002–2024)
The table below shows the annual total liabilities of Hyundai Bioscience Co. Ltd from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩28.27 Billion | +275.85% |
| 2023-12-31 | ₩7.52 Billion | -17.28% |
| 2022-12-31 | ₩9.09 Billion | -52.04% |
| 2021-12-31 | ₩18.96 Billion | -53.86% |
| 2020-12-31 | ₩41.09 Billion | +152.92% |
| 2019-12-31 | ₩16.25 Billion | +20.13% |
| 2018-12-31 | ₩13.52 Billion | -27.32% |
| 2017-12-31 | ₩18.61 Billion | -47.09% |
| 2016-12-31 | ₩35.17 Billion | +86.97% |
| 2015-12-31 | ₩18.81 Billion | +82.23% |
| 2014-12-31 | ₩10.32 Billion | +14.19% |
| 2013-12-31 | ₩9.04 Billion | -31.33% |
| 2012-12-31 | ₩13.16 Billion | -19.23% |
| 2011-12-31 | ₩16.30 Billion | -0.42% |
| 2010-12-31 | ₩16.37 Billion | -25.22% |
| 2009-12-31 | ₩21.89 Billion | -41.11% |
| 2008-12-31 | ₩37.17 Billion | -17.26% |
| 2007-12-31 | ₩44.92 Billion | -69.25% |
| 2006-12-31 | ₩146.06 Billion | -23.73% |
| 2005-12-31 | ₩191.51 Billion | +16.88% |
| 2004-12-31 | ₩163.86 Billion | -5.94% |
| 2003-12-31 | ₩174.21 Billion | +27.61% |
| 2002-12-31 | ₩136.52 Billion | -- |